April 11, 2007 -- Simcere Pharma of China, a company that makes branded generic drugs for the domestic (Chinese) market, has filed to make its IPO and list on the NYSE. The company focuses on first-to-market generics, including an anti-stroke drug and an anti-cancer medication. The Simcere portfolio of drugs treats serious diseases or are in high demand. The company evidently wants to establish partnerships with western biopharma, because part of the proceeds are expected to pay for gaining approval of western drugs in China. More on Simcere...
